Tab%25252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations (GLP-1 and GIP), which enhance insulin secretion and decrease glucagon levels in a glucose-dependent manner. ## Primary Indications Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing * **Standard Dose:** 5 mg orally once daily. * **Maximum Dose:** 5 mg daily. ## Pediatric Dosing Safety and efficacy have not been established in pediatric patients (<18 years). Use is generally not recommended. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required; safe for use in all stages of chronic kidney disease (CKD) and end-stage renal disease (ESRD). * **Hepatic Impairment:** No dose adjustment required. ## Contraindications * History of serious hypersensitivity reactions to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). ## Adverse Effects * **Common:** Nasopharyngitis, diarrhea, arthralgia. * **Serious:** Hypersensitivity reactions (urticaria, angioedema), bullous pemphigoid, severe joint pain, and acute pancreatitis. ## Key Drug Interactions * **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin efficacy. If possible, consider alternative antidiabetic therapies if co-administration is necessary. * **Insulin/Secretagogues:** Increased risk of hypoglycemia when used concomitantly; dose reduction of the secretagogue or insulin may be required. ## Monitoring * **Glycemic control:** HbA1c (typically every 3–6 months), fasting plasma glucose. * **Clinical:** Monitor for signs/symptoms of pancreatitis (persistent, severe abdominal pain) and bullous pemphigoid (blistering or erosions). ## Clinical Pearls * **Renal Advantage:** Unlike other DPP-4 inhibitors (e.g., saxagliptin, sitagliptin), linagliptin does not require renal dose adjustments as it is primarily excreted via the hepatobiliary system. * **Administration:** May be taken with or without food. * **Pancreatitis:** Discontinue immediately if pancreatitis is suspected. * **Weight:** Linagliptin is weight-neutral. *** *Disclaimer: This information is for educational purposes only. Clinical practice guidelines and prescribing information change frequently. Always verify the most current prescribing information via official manufacturer labels or institutional clinical protocols before administering or prescribing any medication.*